Fabien Decaillot

Fabien Decaillot's work experience includes various roles in the scientific and biotechnology fields. From 2022 onwards, they work as a Principal Scientist at Sapreme Technologies BV. Before that, from 2019 to 2023, they served as the Head of Antibody Discovery and Engineering at Hummingbird Bioscience. Prior to that, from 2015 to 2019, they held the position of Principal Scientist at ACM Biolabs. Fabien also worked as a Research Scientist at Singapore Immunology Network (SIgN)/ A*Star from 2009 to 2015. Earlier in their career, they had post-doctorate positions at Rockefeller University from 2008 to 2009 and at Mount Sinai Medical Center from 2003 to 2008. At Rockefeller University, they studied chemokine receptors heterodimerization and its impact on intracellular signaling and breast cancer cell lines migration. At Mount Sinai Medical Center, they focused on the cell biology and mechanisms of mu/ delta opioid receptor dimerization, as well as the peptidomic analysis of mutant mice treated with morphine.

Fabien Decaillot obtained a PhD, Research Doctorate in Molecular Pharmacology from the University Louis Pasteur, with the period of study spanning from 1998 to 2003.